Head of Uro-Oncology Unit. @hospitalclinic. Chair of #eauguidelines Office https://xitter.cf/t.co/REfGeCNmxt In love with Urology!! Passion for life!!!
Barcelona
Joined May 2014
- Tweets15.7K
- Following2.3K
- Followers9.7K
- Likes22K
Maria J. Ribal retweeted
Hundreds of posters. Thousands of hours of research.
Different questions. The same passion.
More effective treatments. Fairer cancer care. For every patient, everywhere.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @urologysummit
Maria J. Ribal retweeted
It was my pleasure & privilege to be part of the ESMO 2026 faculty. Enjoyed role to co-chair the session @MariaJRibal & @BrittSuelmann Great abstracts & presentations. @Mariadesantis @Andreanecchi @MattGalsky @MyEsmo Enjoyed discussing exciting abstracts#NIAGARA #GDFATHER -Neo
Maria J. Ribal retweeted
VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.
Maria J. Ribal retweeted
ctDNA analysis is an increasingly utilised prognostic tool in muscle invasive bladder cancer. In VOLGA 78% of the muscle invasive bladder cancer patients were ctDNA positive at baseline which was prognostic. Also, the combination of perioperative durvalumab and neoadjuvant EV cleared ctDNA in 60% of patients (using the Natera Genome assay which has increased sensitivity). Clearance was associated with much better outcomes. #ESMO26
Maria J. Ribal retweeted
VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert
Great discussions at #ESMO2026!
A pleasure to participate as an invited discussant in today’s Rapid Oral session on #BladderCancer.
From NMIBC to metastatic disease: ADCs, immunotherapy, biomarkers and patient-reported outcomes. The therapeutic landscape is changing rapidly!
But presenting new evidence is only part of the story. Putting results into context and critically assessing their clinical value is essential to understand what should change in daily practice.
Great to share the session with Britt Suelmann and @ProfSyedHussain.
Thank you @myESMO for the invitation and to all the investigators for their outstanding research! And above all : thank you to our patients for their trust.!
#UroOncology #GUOncology
Maria J. Ribal retweeted
🚨 VOLGA is positive! But how much perioperative EV do we really need in MIBC?
Interesting comparison with KEYNOTE-905 at #ESMO26:
🔹 VOLGA (EV + durvalumab): 2-year EFS 64%, OS 78%, pCR 45%. EFS HR 0.51.
🔹 KEYNOTE-905 (EV + pembrolizumab): 2-year EFS 74.7%, OS 79.7%, pCR 57.1%. EFS HR 0.40.
Numerically lower EFS and pCR in VOLGA. Why?
Different patient populations and tumor characteristics? Different study designs? It seems premature to attribute these differences to pembrolizumab vs durvalumab.
But the most intriguing question is how much benefit does adjuvant EV actually add?
VOLGA achieved a significant OS benefit with just 3 neoadjuvant EV cycles and NO adjuvant EV, whereas KEYNOTE-905 planned 9 EV cycles (3 neoadjuvant + 6 adjuvant)—and fewer than half of patients reportedly completed the full planned EV course.
Could pCR and ctDNA clearance help us safely omit adjuvant EV and reduce cumulative toxicity?
⚠️ Cross-trial comparisons are hypothesis-generating, not evidence of superiority or equivalence. Only prospective trials can establish the incremental benefit of adjuvant EV.
More EV ≠ necessarily better outcomes. Let’s identify who really needs it! 🔬
@OncoAlert @weoncologists @tompowles1 @urotoday @Uromigos
@OncoAlert Faculty @DrChoueiri , @tompowles1 , @apolo_andrea , @neerajaiims , @montypal , @Silke_Gillessen , @AOmlin , @brian_rini , @PGrivasMDPhD , @TiansterZhang , @amerseburger , @DrDanielHeng , @HHammersMD , @scocmem , @AndreaNecchi , @AmandaNizamMD , @drenriquegrande , @nataliagandur , @AlbigesL , @cdanicas , @declangmurphy , @seanmmcbride , @shilpaonc , @DrRanaMcKay , @scserendipity1 , @DrYukselUrun , @ravikanesvaran , @BraunMDPhD , @EfstathiouEleni , @mzugman , @crisbergerot @Markuseckstein3
Maria J. Ribal retweeted
KEYNOTE-B15 ctDNA Analysis: Perioperative Enfortumab Vedotin + Pembrolizumab in Cisplatin-Eligible #MIBC. Presented by Jonathan Chatzkel, MD @MoffittNews. #ESMO26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4Bv2fS3 #BladderCancer #PrecisionOncology @myESMO
Maria J. Ribal retweeted
Esciting presentation by @Albert0Briganti ! PROTEUS substudy: adding perioperative apalutamide + ADT to surgery improved EFS in high-risk localized/locally advanced PCa (HR 0.38). Important randomized evidence for intensification! @myESMO #ESMO26 @oncoalert
Maria J. Ribal retweeted
5 phase III perioperative MIBC trials, with differing results.
EV-303, EV-304 and NIAGARA improved EFS/OS, while ENERGIZE and KEYNOTE-866 did not meet their EFS endpoints.
Important differences in patient populations, regimens and trial design. Cross-trial comparisons require caution.
#ESMO26 @OncoAlert
Maria J. Ribal retweeted
SWIU proudly congratulates Dr. E. Ann Gormley on her election as president of the AUA! Her election marks an historic milestone as she will become the first woman to serve as AUA president.
@AmerUrological
Maria J. Ribal retweeted
🏆 El #Clínic ha obtingut 4 premis IQVIA TOP 20, assolint els millors resultats dels darrers cinc anys. Aquest reconeixement posa en valor l'excel·lència assistencial, la qualitat dels resultats i el compromís amb la millora contínua.
👏 Més enllà dels premis, aquest resultat reflecteix la feina diària dels equips que treballen per oferir una atenció d'alta qualitat, innovadora i centrada en les persones.
💚 Gràcies a tots els professionals del Clínic per la vostra dedicació, expertesa i compromís. Aquest reconeixement és vostre.
ℹ️ f.mtr.cool/kp8xae8t32
Avui, una nova jornada del #PlaLidera de l’@hospitalclinic , dedicada a la presa de decisions i al lideratge.
Hem après eines per gestionar millor els reptes del dia a dia, però el més valuós d’aquest programa és tot el que hem construït com a grup de caps d’unitat.
Compartim projectes, dificultats, experiències i decisions. Aprenem els uns dels altres, ens donem suport i ens acompanyem.
Liderar equips no sempre és fàcil, i tenir companys amb qui compartir aquest camí és un privilegi.
Em sento molt afortunada de formar part d’aquest grup de grans professionals i, sobretot, de bons amics.
Perquè el lideratge també es construeix compartint.
#HospitalClínic #Leadership
¡De vuelta de #CAULima2026! 🇵🇪
Un gran congreso, un excelente programa científico y, sobre todo, una nueva oportunidad para compartir experiencias y seguir fortaleciendo la colaboración entre @CAU_URO y @Uroweb
Un placer participar con la EAU Lecture sobre los cambios más relevantes en el manejo del cáncer renal durante los últimos cinco años y en la Arena de Cirugía Robótica, discutiendo los retos de la nefrectomía parcial en tumores complejos.
Dos oportunidades para reflexionar sobre algo esencial: no basta con conocer los últimos avances. Hay que discutir la evidencia, compartir experiencia clínica y entender cómo aplicarla a nuestros pacientes. #eauguidelines
Creo que este es uno de los grandes valores de la colaboración entre sociedades científicas. Aprender de distintas realidades, intercambiar puntos de vista y construir relaciones que nos permitan seguir trabajando juntos.
Mi especial agradecimiento a @UroZampolli por su liderazgo y dedicación a la CAU y por su amistats , a @NicanorCdtac por el gran trabajo organizativo y a todo el equipo de la Sociedad Peruana de Urología por su hospitalidad. Gracias también secretaria CUA por ser tan maravillsoas conmigo.!
Y como siempre, el placer de reencontrarse con buenos amigos, hacer otros nuevos y compartir momentos fuera de las sesiones científicas. Esta vez, además, disfrutando de una ciudad tan especial como Lima.
La ciencia nos reúne, pero son también las personas y las relaciones que construimos las que hacen que estos encuentros merezcan tanto la pena.
¡Gracias, CAU y Perú!
@CAU_URO @Uroweb
#CAU2026 #EAU #Urología #CáncerRenal #eauguidelines
Maria J. Ribal retweeted
AGREE II appraisal revealed marked differences in guideline development quality: EAU-ASCO scored highest across all domains, followed by NCCN and ESMO Bravo for our #eauguidelines #penilecancer @Brouwer_MD_PhD @DrScottTagawa . A joint venture experience that corroborates how multidisciplinar work , rigor, methodology and collaboration allow us to achieve better goals for our patients.!
Penile cancer GL compared (EAU-ASCO, NCCN, ESMO): aligned on principles, divergent where evidence is weak. Methodological quality varies, EAU-ASCO highest on AGREE II.
New in @MUN_journal - pubmed.ncbi.nlm.nih.gov/4282…
@ricautor @AndreaNecchi @CMercinelli @ManfrediCeleste
Maria J. Ribal retweeted
In the new @ScienceMagazine special issue on women's health, a 5★ review of menopause hormone therapy to promote healthy aging
science.org/doi/10.1126/scie…
Maria J. Ribal retweeted
Un reconocimiento al trabajo de todo un equipo.
El Servicio de Urología del @hospitalclinic, que tengo el orgullo de dirigir, reconocido como Servicio con mejor reputación de España por @somosmerco Salud 2025.
Gracias a todos los que lo hacen posible.
ℹ️: drantonioalcaraz.com/mejor-s…
AGREE II appraisal revealed marked differences in guideline development quality: EAU-ASCO scored highest across all domains, followed by NCCN and ESMO Bravo for our #eauguidelines #penilecancer @Brouwer_MD_PhD @DrScottTagawa . A joint venture experience that corroborates how multidisciplinar work , rigor, methodology and collaboration allow us to achieve better goals for our patients.!
Penile cancer GL compared (EAU-ASCO, NCCN, ESMO): aligned on principles, divergent where evidence is weak. Methodological quality varies, EAU-ASCO highest on AGREE II.
New in @MUN_journal - pubmed.ncbi.nlm.nih.gov/4282…
@ricautor @AndreaNecchi @CMercinelli @ManfrediCeleste
Maria J. Ribal retweeted
Antoni Trilla (Barcelona, 1956), epidemiòleg de l'Hospital Clínic i degà de la Facultat de Medicina de la Universitat de Barcelona, s'ha jubilat aquest 30 de setembre. La universitat ho va anunciar el 3 de juliol, però aquest dimecres ha estat el seu últim dia a la UB. Per tancar aquesta etapa, els estudiants de medicina i ciències de la salut de la universitat li han fet un passadís des del deganat fins al paranimf de la facultat.
ara.cat/societat/salut/docto…
#jubilació #antonitrilla #covid-19 #ub
Maria J. Ribal retweeted
Quan algú fa les coses molt bé, amb molt esforç i constància, amb vocació d'ensenyar i aprendre, amb humilitat i discreció i, a més, ho fa de manera excel·lent, passa això. El Prof Dr @ToniTrilla s'ha jubilat com a Degà de Medicina de la @UniBarcelona la primera de l'Estat